Literature DB >> 9311729

The final stage of gene expression: chaperones and the regulation of protein fate.

J Ashkenas1, P H Byers.   

Abstract

Mesh:

Substances:

Year:  1997        PMID: 9311729      PMCID: PMC1715893          DOI: 10.1086/514865

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


× No keyword cloud information.
  38 in total

Review 1.  The N-end rule.

Authors:  A Varshavsky
Journal:  Cell       Date:  1992-05-29       Impact factor: 41.582

Review 2.  Ubiquitination.

Authors:  D Finley; V Chau
Journal:  Annu Rev Cell Biol       Date:  1991

3.  Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis.

Authors:  S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith
Journal:  Cell       Date:  1990-11-16       Impact factor: 41.582

4.  Chaperonin-mediated folding in the eukaryotic cytosol proceeds through rounds of release of native and nonnative forms.

Authors:  G W Farr; E C Scharl; R J Schumacher; S Sondek; A L Horwich
Journal:  Cell       Date:  1997-06-13       Impact factor: 41.582

5.  Protein disaggregation mediated by heat-shock protein Hsp104.

Authors:  D A Parsell; A S Kowal; M A Singer; S Lindquist
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

6.  The molecular chaperone calnexin binds Glc1Man9GlcNAc2 oligosaccharide as an initial step in recognizing unfolded glycoproteins.

Authors:  F E Ware; A Vassilakos; P A Peterson; M R Jackson; M A Lehrman; D B Williams
Journal:  J Biol Chem       Date:  1995-03-03       Impact factor: 5.157

7.  Association of folding intermediates of glycoproteins with calnexin during protein maturation.

Authors:  W J Ou; P H Cameron; D Y Thomas; J J Bergeron
Journal:  Nature       Date:  1993-08-26       Impact factor: 49.962

8.  Defective folding and stable association with protein disulfide isomerase/prolyl hydroxylase of type I procollagen with a deletion in the pro alpha 2(I) chain that preserves the Gly-X-Y repeat pattern.

Authors:  S D Chessler; P H Byers
Journal:  J Biol Chem       Date:  1992-04-15       Impact factor: 5.157

9.  A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency.

Authors:  Y Wu; I Whitman; E Molmenti; K Moore; P Hippenmeyer; D H Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

10.  Calnexin and BiP act as sequential molecular chaperones during thyroglobulin folding in the endoplasmic reticulum.

Authors:  P S Kim; P Arvan
Journal:  J Cell Biol       Date:  1995-01       Impact factor: 10.539

View more
  6 in total

1.  Endoplasmic reticulum quality control of oligomeric membrane proteins: topogenic determinants involved in the degradation of the unassembled Na,K-ATPase alpha subunit and in its stabilization by beta subunit assembly.

Authors:  P Béguin; U Hasler; O Staub; K Geering
Journal:  Mol Biol Cell       Date:  2000-05       Impact factor: 4.138

2.  Role of beta Arg211 in the active site of human beta-hexosaminidase B.

Authors:  Y Hou; D Vocadlo; S Withers; D Mahuran
Journal:  Biochemistry       Date:  2000-05-23       Impact factor: 3.162

Review 3.  Novel pharmacologic therapies for cystic fibrosis.

Authors:  P L Zeitlin
Journal:  J Clin Invest       Date:  1999-02       Impact factor: 14.808

Review 4.  From the ER to the golgi: insights from the study of combined factors V and VIII deficiency.

Authors:  W C Nichols; D Ginsburg
Journal:  Am J Hum Genet       Date:  1999-06       Impact factor: 11.025

Review 5.  Male infertility and the genetics of spermatogenesis.

Authors:  M Okabe; M Ikawa; J Ashkenas
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

6.  Identification of the 6-sulfate binding site unique to alpha-subunit-containing isozymes of human beta-hexosaminidase.

Authors:  R Sharma; H Deng; A Leung; D Mahuran
Journal:  Biochemistry       Date:  2001-05-08       Impact factor: 3.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.